Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa

Annals of Oncology

Volumn 19, Issue 10, 2008, Pages 1749-1753

  Berthold, D R ^a   Pond, G R ^a   de Wit, R ^b   Eisenberger, M ^c   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Docetaxel; Hormone refractory prostate cancer; Mitoxantrone; Second line chemotherapy

Indexed keywords

DOCETAXEL; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MITOXANTRONE; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 53049088662     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn288     Document Type: Article

References (14)

1. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756.
2. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506.
3. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502.
4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513.
5. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245.
6. Ryan CJ, Eisenberger M. Chemotherapy for hormone-refractory prostate cancer: Now it's a question of "when?". J Clin Oncol 2005; 23: 8242.
7. Joshua AM, Nordman I, Venkataswaran R et al. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Intern Med J 2005; 35: 468.
8. Michels J, Montemurro T, Murray N et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: Does sequence matter? Cancer 2006; 106: 1041.
9. Oh WK, Manola J, Babcic V et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006; 67: 1235.
10. Esper P, Mo F, Chodak G et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920.
11. Saad F, Routher D, Ernst S et al. Canadian Urologic Oncology Group (CUOG) phase II multi-center study using docetaxel/predrisone in the second line setting for metastatic hormone-refractory prostate cancer in patients progressing after first line mitoxantrone/prednisone. J Clin Oncol 2005; 23 (Abst 4612).
12. Rosenberg JE, Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 556.
13. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005; 23: 8247.
14. Sternberg CN, Petrylak DP, Witjes F et al. Satraplatin demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. ASCO Proceedings. J Clin Oncol 2007 (Abstr 5019).